High-Quality Covered Puts - 78% Win Rate

Introduction

I’ve written many articles highlighting the advantages options trading and how this technique, when deployed in opportunistic or conservative scenarios on a consistent basis may augment overall portfolio returns while mitigating risk in a meaningful manner. Here, I’d like to focus on leveraging cash to engage in options trading, more specifically selling covered puts. Here, I’d like to cover my approach and results in layman's terms about strategy and empirical outcome with commentary.

In short, I’m committing cash to purchasing shares in the future at an agreed upon price while being paid a premium. Usually, this agreed upon price is significantly higher than it currently trades and when factoring in the premium income, the agreed upon price will be slightly lower than the current price. Put another way; I’m committing cash to buying shares in the future for less than the stock trades today. Therefore, the seller of the option contract (in this case me) believes the price will increase, and the buyer (stock owner) believes the price will fall. The stock owner (buyer) and is purchasing insurance in the event the stock falls (paying for the right to sell the stock at an agreed upon price and date). As the stock appreciates in value and approaches the agreed upon price within the contract time frame the shares will be kept by the owner (buyer), and I keep the premium. If the shares decrease in value, then the shares will be sold to me at the agreed upon price (less the premium). My objective is to leverage cash and generate income without owning the underlying shares of the company via options contracts. Continue reading "High-Quality Covered Puts - 78% Win Rate"

Weekly Futures Recap With Mike Seery

We've asked Michael Seery of SEERYFUTURES.COM to give our INO readers a weekly recap of the Futures market. He has been Senior Analyst for close to 15 years and has extensive knowledge of all of the commodity and option markets.

Michael frequently appears on multiple business networks including Bloomberg news, Fox Business, CNBC Worldwide, CNN Business, and Bloomberg TV. He is also a guest on First Business, which is a national and internationally syndicated business show.

S&P 500 Futures

The S&P 500 in the September contract settled last Friday in Chicago at 2468 while currently trading at 2465 down slightly for the week. I remain very bullish the equity market & if you are long a futures contract the stop loss has been raised to 2448 and in 2 more days that will be raised to 2457. The chart structure has turned excellent because volatility is relatively low except in Thursday's trade when we saw a significant price swing. The Vix, which measures the volatility in the stock market hit a 10-year low in yesterday's trade down to the 11 level which is shocking in my opinion. The bias is to the upside at this time as extremely low-interest rates coupled with a weak U.S. dollar continues to prop up equity prices and I think this trend is going to continue. I'm certainly not recommending any type of bearish position. The S&P 500 is trading far above its 20 and 100-day moving average as this trend is very strong and seems to get stronger on a weekly basis with excellent earnings coming about. This is the perfect storm for higher prices in my opinion so stay long and place the proper stop loss.
TREND: HIGHER
CHART STRUCTURE: SOLID - IMPROVING

Continue reading "Weekly Futures Recap With Mike Seery"

S&P 500: Any Juice Left?

Lior Alkalay - INO.com Contributor


The S&P 500 (CME:SP500) closed for the week at 2,472.10, after hitting an all-time record, after gaining 10.5% year-to-date. The S&P’s forward Price-to-Earnings ratio, a key ratio for investors, is 17.8 above the 10-year average of 14. And this brings up the inevitable pondering; is there any juice left in the S&P 500?

In searching for an answer, the intuitive starting point might be the S&P’s valuation. We’ve already pointed out that the S&P 500 is trading at a high valuation compared to its 10-year average. Furthermore, according to Factset research, earnings for the 500 companies which comprise the S&P 500 are expected to rise by 9.3% as compared to 9.26% in 2016. Now, while that is a solid figure, it also suggests earnings growth is not accelerating and may even suggest the acceleration in earnings growth is over. And if earnings growth is likely to decelerate in the coming years it cannot account for the S&P500’s 17.8 PE ratio. So, there’s no valid reason why the S&P’s valuation would be the catalyst for another surge. Why not? Simply because it's too high. In fact, the real catalyst isn’t within the S&P500 or even within the stock market; instead, the real reason lies within the Bond market. Continue reading "S&P 500: Any Juice Left?"

Markets Dragged Lower By Amazon

Hello traders everywhere. Amazon.com Inc (NASDAQ:AMZN) shares fell a little over 2% after it reported a 77% drop in profit as its rapid and costly expansion into new shopping categories and countries shows no sign of slowing. Amazon is the worst performer on the NASDAQ and the second biggest drag on the S&P 500 today, pulling down both indexes today.

MarketClub's Mid-day Market Report

In economic news, U.S. economic growth for the second quarter came in-line with expectations, the Commerce Department said Friday. The U.S. economy grew at an annualized rate of 2.%, matching estimates.

Key levels to watch next week: Continue reading "Markets Dragged Lower By Amazon"

Cannabis Cancer Stock Up 207% In 2017

Analysis originally distributed on July 19, 2017 By: Michael Vodicka of Cannabis Stock Trades

Cannabis is a proven treatment for cancer patients struggling with the side effects of chemotherapy such as nausea and loss of appetite.

But now, pre clinical research is showing that cannabis could actually be a cancer killer.

A group of scientists recently reported that THC and CBD slowed the growth and even killed certain cancer cells – including breast, brain and liver cancer – when grown in a lab.

Animal studies also suggest that cannabis could be a cancer killer.

A study conducted by Complutense University, one of the oldest and largest universities in Europe located in Madrid, showed that an injection of a synthetic THC eliminated malignant brain tumors in 1/3 of the rats studied while extending the life of another 1/3. Continue reading "Cannabis Cancer Stock Up 207% In 2017"